Breakthrough events (patients 3 and 5 had no events)
| Patient . | Time taken between initiation of pegcetacoplan and BTH (d)∗ . | Precipitating event at BTH . | LDH during stable pegcetacoplan treatment (× ULN) . | LDH at time of breakthrough (× ULN) . | Time taken for LDH return baseline (d) . | Hb baseline (g/L) . | Hb at BTH (g/L) . | Time taken for Hb to fall (d) . | Drop in Hb (g/L) . | Management of BTH event . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1a | 262 | Infection | Normal | 4.9 | 9 | 97 | 86 | 0 | 11 | Eculizumab single dose (900 mg) |
| 1b | 254 | COVID-19 and flu vaccination | 1.4 | 5.1 | 19 | 130 | 89 | 5 | 41 | Eculizumab 2 doses (900 mg); increase pegcetacoplan dosing frequency to every 3 d |
| 1c | 315 | Norovirus infection | 1.4 | Hemolyzed† | NA | 145 | 117 | 1 | 28 | Eculizumab single dose (900 mg) |
| 2 | 174 | Infection (site unclear) | Normal | 2.1 | 13 | 103 | 78 | 0 | 25 | No change |
| 4a | 19 | No event | NA∗ | 4.9 | 20 | 120 | 102 | 2 | 18 | Eculizumab restarted (900 mg) every 2 wk |
| 4b | 60 | No event | NA∗ | 6.5 | 22 | 118 | 76 | 0 | 42 | Eculizumab increased (1200 mg) every 2 wk; increase pegcetacoplan dosing frequency to every 3 d |
| 4c | Already on combination treatment | Lower respiratory tract infection | Normal | 4.2 | Awaited | 120 | 71 | 0 | 39 | Eculizumab increased (1500 mg) every 2 wk; daily pegcetacoplan for 3 d |
| Patient . | Time taken between initiation of pegcetacoplan and BTH (d)∗ . | Precipitating event at BTH . | LDH during stable pegcetacoplan treatment (× ULN) . | LDH at time of breakthrough (× ULN) . | Time taken for LDH return baseline (d) . | Hb baseline (g/L) . | Hb at BTH (g/L) . | Time taken for Hb to fall (d) . | Drop in Hb (g/L) . | Management of BTH event . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1a | 262 | Infection | Normal | 4.9 | 9 | 97 | 86 | 0 | 11 | Eculizumab single dose (900 mg) |
| 1b | 254 | COVID-19 and flu vaccination | 1.4 | 5.1 | 19 | 130 | 89 | 5 | 41 | Eculizumab 2 doses (900 mg); increase pegcetacoplan dosing frequency to every 3 d |
| 1c | 315 | Norovirus infection | 1.4 | Hemolyzed† | NA | 145 | 117 | 1 | 28 | Eculizumab single dose (900 mg) |
| 2 | 174 | Infection (site unclear) | Normal | 2.1 | 13 | 103 | 78 | 0 | 25 | No change |
| 4a | 19 | No event | NA∗ | 4.9 | 20 | 120 | 102 | 2 | 18 | Eculizumab restarted (900 mg) every 2 wk |
| 4b | 60 | No event | NA∗ | 6.5 | 22 | 118 | 76 | 0 | 42 | Eculizumab increased (1200 mg) every 2 wk; increase pegcetacoplan dosing frequency to every 3 d |
| 4c | Already on combination treatment | Lower respiratory tract infection | Normal | 4.2 | Awaited | 120 | 71 | 0 | 39 | Eculizumab increased (1500 mg) every 2 wk; daily pegcetacoplan for 3 d |
If more than 1 breakthrough event occurred per patient, this was indicated as a, event 1; b, event 2; and c, event 3.
LDH was not obtained on single-agent pegcetacoplan because of limited time on single-agent treatment.
Samples were hemolyzed. LDH before the event was normal and after the event was 1.1× ULN.